# Study of NG-350A Plus Pembrolizumab in Metastatic or Advanced Epithelial Tumours (FORTIFY)

Source: https://onco.cc/trials/nct05165433/  
OnCo record `nct05165433` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of NG-350A run by Akamis Bio, completed.

## Summary

Study of NG-350A Plus Pembrolizumab in Metastatic or Advanced Epithelial Tumours (FORTIFY) is a phase 1 interventional study registered as NCT05165433 by Akamis Bio, with 14 participants enrolled, started 2022-04-13, primary completion reached 2025-08-29. Conditions recorded: Epithelial Tumor, Metastatic Cancer. Interventions recorded: NG-350A plus Pembrolizumab.

## Fields

- Kind: Trial
- Status: completed
- Last checked: 2026-11-04
- Tags: pipeline; ctgov-ingest
- Registry id: NCT05165433
- Phase: 1
- Setting: A Multicentre, Open-label, Non-randomized, Phase 1a/1b Study of NG-350A, a Tumour-selective Anti-CD40-expressing Adenoviral Vector, in Combination With Pembrolizumab in Patients With Metastatic or Advanced Epithelial Tumours
- Sponsor: Akamis Bio
- Enrolled: 14

## Sources

- ClinicalTrials.gov NCT05165433: https://clinicaltrials.gov/study/NCT05165433

## Connected records

- drugs: [NG-350A](https://onco.cc/drugs/ng-350a/)
- companies: [Akamis Bio](https://onco.cc/companies/akamis-bio/)

---
JSON: https://onco.cc/api/v1/entities/nct05165433.json